Presentation is loading. Please wait.

Presentation is loading. Please wait.

Systematic Reviews and the American Academy of Pediatrics Virginia A. Moyer, MD, MPH Professor of Pediatrics Baylor College of Medicine.

Similar presentations


Presentation on theme: "Systematic Reviews and the American Academy of Pediatrics Virginia A. Moyer, MD, MPH Professor of Pediatrics Baylor College of Medicine."— Presentation transcript:

1 Systematic Reviews and the American Academy of Pediatrics Virginia A. Moyer, MD, MPH Professor of Pediatrics Baylor College of Medicine

2 American Academy of Pediatrics Founded in 1930 as an independent pediatric forum to address children’s needs 60,000 members worldwide 34,000 certified by the American Board of Pediatrics and designated as Fellows of the AAP The mission of the American Academy of Pediatrics is to attain optimal physical, mental, and social health and well-being for all infants, children, adolescents, and young adults. To accomplish this mission, the Academy shall support the professional needs of its members.

3 Categories of AAP Policy Policy Statement - A statement of advocacy, direction, or a public health position of concern to the Academy, including recommendations Clinical Report - The Clinical Report (CR) offers guidance for the pediatrician in the clinical setting, addressing best practices and state of the art medicine, not supposed to include formal recommendations. Clinical Practice Guideline - Based on a comprehensive literature review and data analyses with formal rules of evidence in support of each recommendation made. Technical Report - Based on a literature review and data analyses but does not contain recommendations.

4

5 Methodology for CPG Development “As far as possible, conclusions about optimal management and recommendations to the clinician will be based on a rigorous analysis of current literature”

6 Rules of Evidence “Authoring entities should consider using formal rules of evidence in the development of the document, following the format of the US Preventive Services Task Force Guide to Clinical Preventive Services, 2nd Edition (1996).”

7 Aggregate Evidence Quality Next, guideline developers must consider the quality of the aggregate of studies that bear on the issue. Judging the strength of a body of evidence requires careful consideration of the consistency of the results of individual studies, the magnitude of the effect that the studies detect, and the individual and aggregate sample sizes of these studies. West S, King V, Carey TS, et al. Systems to Rate the Strength of Scientific Evidence. Evidence Report/Technology Assessment no. 47. Research Triangle Park, NC: Research Triangle Institute- University of North Carolina Evidence-Based Practice Center; 2002. AHRQ Publication no. 02-E016

8 Grading Recommendation Strength Evidence Quality Preponderance of Benefit or Harm Balance of Benefit and Harm A. Well designed RCTs or diagnostic studies on relevant population B. RCTs or diagnostic studies with minor limitations;overwhelmingly consistent evidence from observational studies C. Observational studies (case-control and cohort design) D. Expert opinion, case reports, reasoning from first principles X. Exceptional situations where validating studies cannot be performed and there is a clear preponderance of benefit or harm Strong Rec Option No Rec Classifying Recommendations for Clinical Practice Guidelines. Pediatrics 2004;114(3):874-877

9 The Reality of AAP SRs “A thorough review of all relevant databases with standardized search terms is required; We do not always require more than one reviewer in rating the article- we should, but it's not always feasible. RCTs are better than observational studies are better than case reports/first principles… Articles outside of the years searched are not allowed to be included in determining the strength of evidence/recommendation, but can be cited in supporting text. If an article comes out that will change the strength, then we try to update the full lit review.” In-house SRs are internally funded, but available funding is limited, which may significantly affect quality and timeline. Personal communication – CPG Manager

10 EPC evidence reviews “The TEP was well rounded and included a number of members who are on the AOM guideline committee… I have also been in frequent communication with AHRQ to help move the report along while we simultaneously began the guideline process using the AHRQ draft… Unfortunately there were numerous delays. Administratively the draft sat at AHRQ for several months before it was put out for comment. Several members of the guideline committee including those on the TEP had problems with the draft. Currently I believe the draft is undergoing significant changes and we do not know when we will see newer versions and a final product… Since we need the AHRQ report for our evidence base, we will not meet our target date. In addition we will have to attempt to review new literature to keep the guideline up to date.” “As of right now, it's at least 2 years from topic submission till there's an evidence review, and then another 2 years till there's a guideline. It doesn't make the committees very receptive to writing guidelines.” Chairs, Guideline Committees

11 AAP “Endorsed” Guidelines Use COGS checklist to assess quality COGS has some SR assessment questions

12 Looking ahead Increasing need for high quality evidence reviews  Comprehensive reviews for CPGs  Limited scope reviews for Policy Statements and Clinical Reports Significant cost and limitations of in-house evidence reports for CPGs Significant time issues with external evidence reports for CPGs Significant methodology issues for limited scope reviews AAP would welcome uniform guidelines, but these need to be practical and applicable to multiple situations.


Download ppt "Systematic Reviews and the American Academy of Pediatrics Virginia A. Moyer, MD, MPH Professor of Pediatrics Baylor College of Medicine."

Similar presentations


Ads by Google